MedTrace Logo

Role of Glare and Spectral Filtering on Contrast Sensitivity: A Pilot Study

NCT05582304 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-01-31

Study results available
· View outcomes & findings →

Summary

This will be a split-plot design, randomized, parallel, double-masked feasibility study to evaluate the role of a test lens on contrast sensitivity with and without glare.

Conditions

  • Visual Acuity

Interventions

DEVICE

Test Lens

ACUVUE OASYS MAX 1-Day with TearStable Technology and OptiBlue Light Filter

DEVICE

Control Lens

ACUVUE OASYS 1-Day with HydraLuxe Technology

Sponsors & Collaborators

  • Johnson & Johnson Vision Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Vision Care, Inc. Clinical Trial · Johnson & Johnson Vision Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2022-12-08
Completion
2022-12-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05582304 on ClinicalTrials.gov